Dr. Chung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
120 Dillon Dr
Spartanburg, SC 29307Phone+1 864-699-5700Fax+1 864-699-5701
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2003
- Johns Hopkins UniversityResidency, Internal Medicine, 1995 - 1999
- University of North Carolina at Chapel Hill School of MedicineClass of 1995
Certifications & Licensure
- SC State Medical License 2011 - 2025
- NY State Medical License 1999 - 2013
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
- Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 3 citationsPhase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.Neil S Horowitz, Wei Deng, Ivy Peterson, Robert S Mannel, Spencer Thompson
Journal of Clinical Oncology. 2024-06-01 - 1 citationsEffects ofon Breast Cancer Cells: An Alternative to Chemotherapy?Zoe Sanders, Bridgette A Moffitt, Madeleine Treaster, Ashley Larkins, Nicholas Khulordava
Metabolites. 2023-10-16 - 5 citationsPhase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.Xiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, R Donald Harvey, Ki Young Chung
Investigational New Drugs. 2022-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: